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Background: Hypertriglyceridemia and postprandial hyperlipidemia is thought to play an important role in
atherosclerosis, but to select patients at high-risk for cardiovascular diseases is difficult with triglycerides (TG) alone
in these patients.
Methods: To predict postprandial hyperlipidemia without inconvenient test meal loading, we examined lipid
concentrations before and after test meal loading and fasting adiponectin, and investigated which of these other
than TG were significant during the fasting period in 45 healthy individuals (men: women, 26:19).
Results: TG, remnant-like particle-cholesterol and -triglyceride (RemL-C, RLP-C, and RLP-TG), and TG/apolipoprotein
(apo)B were significantly elevated after loading and fasting values significantly and positively correlated with
incremental area under the curve (iAUC) (r=0.80, r=0.79, r=0.63, r=0.58, r=0.54; p<0.0001). Fasting adiponectin
positively correlated with fasting high-density lipoprotein-cholesterol (r=0.43, p<0.005) and apoA-I (r=0.34, p<0.05),
and negatively correlated with iAUC of TG, RemL-C, RLP-C, RLP-TG, and TG/apoB (r=−0.37, r=−0.41, r=−0.37, r=−0.36,
r=−0.37; p<0.05). We constructed the model of multivariable linear regression analysis without fasting TG. In the
sex-, BMI-, age-, and waist circumference-adjusted analysis of postprandial TG elevation 2 h after test meal loading
in all participants, RemL-C, RLP-C, RLP-TG, and TG/apoB were significant factors, but adiponectin was not.
Conclusion: Fasting triglyceride-rich lipoprotein-related values, especially RemL-C, RLP-C, RLP-TG, and TG/apoB are
useful predictors of postprandial hyperlipidemia in young healthy individuals. Although fasting adiponectin
concentration correlated with the iAUCs for TG, RemL-C, RLP-C, RLP-TG, and TG/apoB, it was not a significant
predictor of postprandial hyperlipidemia in multivariable linear regression analysis.
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Epidemiological studies have recently shown that hyper-
triglyceridemia is associated with atherosclerosis, but the
independence of the serum triglycerides (TG) concentra-
tion as a causal factor in promoting cardiovascular dis-
eases (CVD) remains debatable and to select patients at
high-risk for CVD is difficult with TG alone [1-3]. Indi-
viduals with mild hypertriglyceridemia without other
metabolic disorders or severe hypertriglyceridemia such
as primary chylomicronemia rarely have CVD.* Correspondence: fujioka@nutr.kobegakuin.ac.jp
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reproduction in any medium, provided the orPostprandial hyperlipidemia is thought to play an
important role in atherosclerosis, and concentrations of
non-fasting TG are superior to those of fasting TG for
predicting CVD [4-7]. Many studies have revealed that
triglyceride-rich lipoproteins (TRL), especially chylo-
micron and very-low-density lipoprotein (VLDL) rem-
nants, are atherogenic and that delayed removal of
chylomicron remnants from the bloodstream induces
postprandial hyperlipidemia [8-10]. However, screening
large numbers of individuals using fat loading tests is
inconvenient and neither a definition nor a standard
method for predicting postprandial hyperlipidemia
besides postprandial TG elevation has been established.
These circumstances present a challenge in terms of
how to distinguish patients at high-risk of CVD basedLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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serum concentrations of remnant lipoproteins and apoli-
poprotein B-48 (apoB-48) besides TG might indicate
postprandial hyperlipidemia even among normolipi-
demic individuals[11].
Adipocytes secrete adiponectin, which is a 224-amino-
acid plasma protein [12,13]. Serum adiponectin concen-
trations are paradoxically reduced in individuals with a
large visceral fat mass, and adiponectin plays a significant
role in glucose and lipid metabolism [13-15]. However,
few studies have examined the relationship between serum
adiponectin concentrations and postprandial hyperlipid-
emia. Rubin et al. demonstrated that postprandial TG
concentrations correlate with fasting adiponectin con-
centrations in 45 - 65-year-old individuals, including
those with metabolic syndrome [16]. Maruyama et al.
reported that serum concentrations of high molecular
weight (HMW) adiponectin are associated with those of
TG and remnant-like particle-triglyceride (RLP-TG) in
individuals with type 1 diabetes before and after test meal
loading [17].
Thus, the significance of adiponectin in postprandial
hyperlipidemia needs to be clarified. Here, we used mul-
tivariable linear regression analysis to identify which fac-
tors among remnant lipoproteins, adiponectin and other
particles during fasting are significant for predicting post-
prandial hyperlipidemia.Methods
Participants and physical examination
We recruited 45 healthy individuals (men/women, 26/19)
who had never been treated for diseases or taken drugs
for at least 3 months prior to the study. We used data
from 24 participants that we had previously analyzed
[11] and we added another 21 individuals for the
present study. All of the recruits provided written,
informed consent to participate in the study. The insti-
tutional ethics committee of Kobe Gakuin University
(HEB080701-1) approved the study protocol, which pro-
ceeded according to the Declaration of Helsinki. We
measured the waist circumference and computed the
body mass index (BMI) of all participants by dividing
body weight by the square of the height (kg/m2).Study protocol
The study proceeded as previously described [11]. Test
meal A was developed by the Japanese Diabetes Society
to assess both postprandial hyperglycemia and hyperlip-
idemia. This meal consisted of cream of chicken soup, a
biscuit and custard pudding. The total 450 kcal of energy
was derived from 57.6g of carbohydrate (51.4% of the en-
ergy balance), 17.2g of protein (15.3%), and 16.6 g of fat
(33.3%), which is a slightly higher ratio of fat than thatfound in a typical Japanese breakfast (20% - 25%). Blood
samples were obtained between 9 and 10 AM after 12 h
of fasting and at 1, 2, 4, 6 and 8 h after test meal loading.Blood analysis
Serum concentrations of HMW adiponectin and plasma-
oxidized low-density lipoproteins (LDL) were determined
using sandwich enzyme-linked immunosorbent assays
(ELISA) (Fujirebio, Tokyo, Japan and Kyowa Medex,
Tokyo, Japan, respectively). Serum concentrations of TG,
total cholesterol, high-density lipoprotein-cholesterol
(HDL-C) were determined enzymatically (Kyowa Medex,
Tokyo, Japan). For low-density lipoprotein-cholesterol
(LDL-C), we used the commercial kit by the selective
solubilization method (Determiner L LDL-C, Kyowa
Medex) because it is impossible to use Friedewald’s for-
mula in the postprandial cases. Serum concentrations of
apoA-I, apoA-II, apoB, apoC-II, apoC-III, and apoE
were measured using turbidimetric immunoassays
(Nittobo, Tokyo, Japan). Serum small dense LDL-
cholesterol (sd-LDL-C) concentrations were measured
using a precipitation method (Denka Seiken, Tokyo,
Japan) [18]; serum concentrations of remnant-like
particle-cholesterol (RLP-C) and RLP-TG were deter-
mined using immune adsorption (JIMRO II, Otsuka
Pharmaceutical, Tokyo, Japan) [19]; serum remnant
lipoprotein cholesterol (RemL-C) concentrations were
measured using a homogeneous assay (MetaboLead
RemL-C, Kyowa Medex) [20]. Serum high-sensitivity
C-reactive protein (hs-CRP) concentrations were deter-
mined using nephelometry (Dade Behring, Deerfield, IL,
USA). Plasma glucose concentrations were determined
enzymatically. Glycosylated hemoglobin A1c (HbA1c)
values were determined using HPLC. Serum insulin con-
centrations were measured using an enzyme immuno-
assay. Non-HDL-C concentrations were computed by
subtracting the value of HDL-C from that of TC.Statistical analysis
Values are expressed as means ± SD. Data below the
threshold of RLP-C (< 2.0mg/dl) or RLP-TG (< 15mg/dL)
were treated as 2.0 or 15 mg/dL, respectively. TG, RemL-
C, RLP-C, RLP-TG, TG/apoB, and adiponectin were
transformed into logarithmic values. The statistical signifi-
cance of the data was evaluated using Welch’s t-test or
repeated ANOVA with Dunnett’s test. Postprandial
changes in values of TG, RemL-C, RLP-C, RLP-TG, or
TG/apoB were quantified by calculating the incremental
area under the curve (iAUC), which was estimated as the
difference between the area defined below the baseline
concentration and the area under the curve in each factor
or parameter from 1 h to 8 h after test meal loading.
Nagata et al. Lipids in Health and Disease 2012, 11:146 Page 3 of 11
http://www.lipidworld.com/content/11/1/146Correlations between adiponectin and lipids as well as
other factors were calculated using the formula for Pear-
son’s correlation coefficient.
Independent predictors of TG at 2 h after test meal
loading were identified by multivariable linear regression
analysis adjusted with sex, BMI, age, waist circumfer-
ence. Candidate predictors (RemL-C, RLP-C, RLP-TG,
TG/apoB, and adiponectin) were analyzed separately be-
cause of correlation among candidate predictors. The
purpose of our study was to elucidate the factors that
predict postprandial hyperlipidemia besides TG, because
it is difficult to select high-risk patients with TG alone.
Therefore, we did not investigate fasting TG as candi-
date predictor in regression model. Data were statisti-
cally analyzed using SPSS Statistics 17.0 (IBM, Somers,
NY, USA) and R version 2.12.1 (R Foundation for Statis-
tical Computing, Vienna, Austria). Two-tailed values of
p < 0.05 were considered statistically significant.Results
Characteristics of subjects
Table 1 shows the characteristics of the 26 men and 19
women participants, except for LPL mass (total 21; 15
men and 6 women). Although all factors were within
normal limits, the values of height, body weight, waist
circumference, and hs-CRP concentration were higher in
men than in women. On the other hand, adiponectin
concentration was higher in women than in men.Fasting and postprandial concentrations of lipids and
their parameters
Tables 2A (all participants) shows the changes of lipid,
glucose, and insulin concentrations before and after test
meal loading. Since some metabolic factors in Table 1Table 1 Baseline characteristics of study participants
Total Men Women
Sex (n) 45 26 19
Age (years) 21.5 ± 1.3 21.4 ± 1.5 21.7 ± 0.9
Height (m) 1.66 ± 0.08 1.70 ± 0.06 1.61 ± 0.07*
Body weight (kg) 58.1 ± 8.8 61.8 ± 9.3 53.1 ± 4.9†
Waist circumference (cm) 73.8 ± 7.8 73.5 ± 7.5 67.9 ± 5.44‡
BMI (kg/m2) 21.0 ± 2.3 21.4 ± 2.8 20.5 ± 1.4
HbA1c (%) 4.9 ± 0.2 4.91 ± 0.23 4.91 ± 0.25
Hs-CRP (mg/dL) 0.04 ± 0.02 0.05 ± 0.02 0.03 ± 0.02§
Adiponectin (μg/mL) 5.53 ± 3.13 4.51 ± 2.38 6.93 ± 3.54‡
LPL mass (ng/mL) 44.1 ± 12.7 42.3 ± 12.1 48.8 ± 15.3
BMI, body mass index; HbA1c, glycated hemoglobin A1c; Hs-CRP, high-sensitivity
C-reactive protein; LPL, lipoprotein lipase. Values are means ± SD. Adiponectin
values were transformed into logarithmic values. *p < 0.0001, †p< 0.001, ‡p < 0.01,
§p <0.05 vs. men (Welch’s t-test). All data were derived from 45 subjects (men 26,
women 19) except LPL mass (total 21, men 15, women 6).differed between men and women, we also compared
these data in Table 2B (men) and C (women).
The concentrations of all parameters were within nor-
mal limits or at low ranges during the fasting period
(time 0). Fasting values of TG*, RemL-C*, RLP-C†, RLP-
TG†, non-HDL-C/HDL-C*, LDL-C/HDL-C* and apoB/
apoA-I* were significantly greater in men than in
women (*p < 0.05; †p < 0.005, Welch’s t-test). Fasting
RLP-TG concentrations in all women were undetectable
(<15 mg/dL), and we set fasting RLP-TG concentration
as 15 mg/dL in Table 2C. On the other hand, HDL-C
concentrations were significantly lower in men than in
women (p < 0.05, Welch’s t-test).
Serum concentrations of TG, RLP-C, RLP-TG, insu-
lin and plasma glucose concentrations were signifi-
cantly elevated after, compared with before loading in
all participants (Table 2A). Serum RemL-C concentra-
tions peaked at 1 h and were restored within 4 h, but
this elevation had no significance. On the other hand,
TC, LDL-C, HDL-C, sd-LDL-C, oxidized LDL, apoA-I,
apoA-II, apoB, apoC-II, apoC-III, and apoE concentra-
tions were not elevated, which were consistent with
our previous findings[11].
We also analyzed several atherogenic indicators and
found that the values of non-HDL-C, non-HDL-C/
HDL-C, LDL-C/HDL-C, apoB/apoA-I, and non-HDL-C/
apoB were not significantly altered, whereas the value
of TG/apoB was significantly elevated. Serum concen-
trations of TG, RLP-C, RLP-TG, TG/apoB and insulin
separately analyzed in men and in women (Table 2B
and C, respectively), were significantly elevated after,
compared with before test meal loading.
The iAUC for TG, RemL-C, RLP-C, RLP-TG, and TG/
apoB, which were significantly increased after test meal
loading, were significantly greater in men than in women
(p < 0.05, p < 0.005, p < 0.005, p < 0.01, p < 0.05, respect-
ively, Welch’s t-test).
Fasting serum values and the iAUC of each factor and
parameter significantly and positively correlated in all
participants (Fig. 1). Fasting serum values for TG,
RemL-C, RLP-C, RLP-TG and TG/apoB in men (n = 26)
also significantly and positively correlated with the iAUC
(r = 0.78, p < 0.0001; r = 0.78, p < 0.0001; r = 0.60,
p < 0.005; r = 0.54, p < 0.005; r = 0.81, p < 0.0001,
respectively). Fasting serum values for TG, RemL-C,
and TG/apoB in women (n = 19) significantly and
positively correlated with the iAUC (r = 0.77, r = 0.76,
r = 0.79, respectively; all p < 0.0001), but relationships
between fasting serum values of RLP-TG and the
iAUC could not be estimated because fasting RLP-TG
was undetectable in all of the women. Despite the
small number of female participants, these results
indicated that fasting values of RemL-C, RLP-C,
RLP-TG, and TG/apoB in addition to TG are useful
Table 2 Lipid and glucose parameters for before and 1 – 8 h after loading with test meal
A. All participants Elapsed time (h)
0 1 2 4 6 8
TC (mg/dL) 182.4 ± 32.8 180.2 ± 32.8 178.2 ± 31.3 180.4 ± 30.1 184.0 ± 31.6 188.2 ± 32.5
LDL-C (mg/dL) 98.5 ± 26.1 96.3 ± 25.5 95.6 ± 25.5 96.7 ± 24.7 99.8 ± 25.6 102.1 ± 26.2
HDL-C (mg/dL) 70.1 ± 15.4 68.3 ± 15.4 66.2 ± 14.1 68.3 ± 15.0 70.2 ± 15.7 72.0 ± 16.0
Sd-LDL-C (mg/dL) 22.4 ± 12.1 19.8 ± 8.8 18.8 ± 8.5 18.6 ± 7.1 18.6 ± 7.1 19.0 ± 7.0
OxLDL (U/mL) 7.38 ± 4.96 7.04 ± 4.98 7.25 ± 5.74 7.41 ± 5.53 7.71 ± 5.41 8.38 ± 5.46
TG (mg/dL) 69.8 ± 31.2 92.1 ± 41.0* 103.9 ± 51.4† 72.9 ± 40.4 70.7 ± 34.3 53.9 ± 23.8
Non-HDL-C (mg/dL) 112.3 ± 30.1 112.0 ± 29.9 112.0 ± 29.3 112.0 ± 28.4 113.8 ± 28.7 116.3 ± 29.4
RemL-C (mg/dL) 3.51 ± 1.84 4.35 ± 2.11 4.29 ± 2.46 3.90 ± 2.38 3.22 ± 1.61 2.98 ± 1.40
RLP-C (mg/dL) 3.20 ± 1.30 4.22 ± 1.91* 5.01 ± 2.42‡ 3.88 ± 1.94 3.03 ± 1.02 2.82 ± 0.88
RLP-TG (mg/dL) 16.3 ± 4.0 25.5 ± 14.4† 32.6 ± 21.8‡ 21.1 ± 12.3 15.8 ± 3.4 15.3 ± 2.0
ApoA-I (mg/dL) 161.2 ± 26.6 159.8 ± 27.3 158.7 ± 25.2 160.3 ± 25.2 163.3 ± 26.4 165.7 ± 27.0
ApoA-II (mg/dL) 37.6 ± 6.0 37.3 ± 6.2 36.8 ± 6.0 37.4 ± 5.9 37.7 ± 5.9 38.4 ± 6.1
ApoB (mg/dL) 66.6 ± 15.3 65.7 ± 15.1 65.0 ± 14.5 66.2 ± 14.5 67.9 ± 14.8 69.3 ± 15.2
ApoC-II (mg/dL) 3.2 ± 1.2 3.3 ± 1.2 3.3 ± 1.2 3.3 ± 1.2 3.3 ± 1.1 3.3 ± 1.1
ApoC-III (mg/dL) 9.5 ± 2.4 9.8 ± 2.5 9.4 ± 2.3 9.2 ± 2.2 9.0 ± 2.1 9.0 ± 2.2
ApoE (mg/dL) 4.3 ± 1.1 4.3 ± 1.1 4.3 ± 1.0 4.2 ± 1.1 4.1 ± 1.0 4.2 ± 1.1
Non-HDL-C/HDL-C 1.70 ± 0.73 1.75 ± 0.75 1.80 ± 0.75 1.75 ± 0.76 1.73 ± 0.74 1.72 ± 0.73
LDL-C/HDL-C 1.50 ± 0.60 1.50 ± 0.61 1.52 ± 0.61 1.50 ± 0.61 1.51 ± 0.60 1.50 ± 0.60
ApoB/apoA-I 0.43 ± 0.13 0.42 ± 0.13 0.42 ± 0.13 0.43 ± 0.13 0.43 ± 0.13 0.43 ± 0.13
Non-HDL-C/apo B 1.67 ± 0.10 1.69 ± 0.10 1.71 ± 0.11 1.68 ± 0.10 1.67 ± 0.10 1.67 ± 0.10
TG/apoB 1.06 ± 0.44 1.41 ± 0.56§ 1.61 ± 0.71‡ 1.25 ± 0.61 0.93 ± 0.40 0.79 ± 0.32
Plasma glucose (mg/dL) 89.9 ± 5.7 96.9 ± 20.0§ 87.5 ± 10.8 87.6 ± 4.9 88.1 ± 5.7
Insulin (μU/mL) 5.6 ± 2.4 42.4 ± 24.6‡ 18.5 ± 14.1‡ 5.0 ± 2.2 4.2 ± 2.1
B. Men
TC (mg/dL) 183.1 ± 33.8 181.4 ± 34.5 180.0 ± 33.3 182.4 ± 32.5 185.0 ± 33.2
LDL-C (mg/dL) 101.1 ± 28.2 99.0 ± 27.5 99.3 ± 27.7 99.8 ± 26.9 102.7 ± 27.8
HDL-C (mg/dL) 66.3 ± 16.7 64.7 ± 17.4 62.5 ± 15.5 65.1 ± 17.2 66.5 ± 17.4
Sd-LDL-C (mg/dL) 23.9 ± 11.0 22.2 ± 10.2 21.4 ± 9.5 20.4 ± 9.0 19.8 ± 8.0
OxLDL (U/mL) 7.98 ± 5.48 7.91 ± 5.54 8.12 ± 6.19 8.32 ± 6.11 8.70 ± 6.22
TG (mg/dL) 78.9 ± 36.0 106.3 ± 45.1 119.5 ± 58.9† 94.8 ± 51.2 68.6 ± 33.7
Non-HDL-C (mg/dL) 116.8 ± 32.5 116.8 ± 32.2 117.5 ± 31.8 117.3 ± 31.1 118.5 ± 31.2
RemL-C (mg/dL) 4.08 ± 2.13 4.99 ± 2.42 5.16 ± 2.81 4.69 ± 2.80 3.67 ± 1.91
RLP-C (mg/dL) 3.62 ± 1.51 5.00 ± 2.03* 5.82 ± 2.76‡ 4.53 ± 2.23 3.31 ± 1.13
RLP-TG (mg/dL) 17.3 ± 5.1 30.0 ± 16.7§ 37.8 ± 26.2‡ 24.7 ± 15.2 16.4 ± 4.5
ApoA-I (mg/dL) 155.7 ± 29.2 154.4 ± 29.9 154.3 ± 28.7 155.2 ± 29.0 157.9 ± 29.4
ApoA-II (mg/dL) 33.8 ± 6.7 38.7 ± 6.8 38.4 ± 6.6 38.8 ± 6.5 39.1 ± 6.7
ApoB (mg/dL) 68.8 ± 16.3 68.3 ± 16.3 67.5 ± 15.6 68.8 ± 15.8 70.5 ± 16.0
ApoC-II (mg/dL) 3.5 ± 1.1 3.6 ± 1.1 3.6 ± 1.2 3.6 ± 1.2 3.6 ± 1.1
ApoC-III (mg/dL) 9.7 ± 2.6 10.2 ± 2.8 9.8 ± 2.7 9.5 ± 2.5 9.2 ± 2.3
ApoE (mg/dL) 4.1 ± 1.1 4.1 ± 1.1 4.2 ± 1.0 4.0 ± 1.1 3.9 ± 1.0
Non-HDL-C/HDL-C 1.90 ± 0.85 1.96 ± 0.88 2.02 ± 0.87 1.96 ± 0.89 1.94 ± 0.86 1.92 ± 0.86
LDL-C/HDL-C 1.64 ± 0.71 1.66 ± 0.72 1.70 ± 0.70 1.66 ± 0.72 1.67 ± 0.71 1.66 ± 0.71
ApoB/apoA-I 0.46 ± 0.15 0.46 ± 0.15 0.46 ± 0.15 0.46 ± 0.16 0.46 ± 0.15 0.46 ± 0.15
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Table 2 Lipid and glucose parameters for before and 1 – 8 h after loading with test meal (Continued)
Non-HDL-C/apo B 1.69 ± 0.10 1.70 ± 0.11 1.73 ± 0.12 1.70 ± 0.11 1.67 ± 0.10 1.68 ± 0.11
TG/apoB 1.17 ± 0.52 1.58 ± 0.63 1.79 ± 0.84† 1.41 ± 0.73 1.00 ± 0.49 0.86 ± 0.39
Plasma glucose (mg/dL) 91.1 ± 5.9 97.7 ± 19.9 85.7 ± 9.7 89.2 ± 4.6 88.7 ± 5.9 87.7 ± 5.9
Insulin (μU/mL) 5.0 ± 2.1 33.6 ± 13.7‡ 11.6 ± 7.4† 4.5 ± 2.0 3.8 ± 2.3 3.7 ± 1.8
C. Women
TC (mg/dL) 181.4 ± 32.3 178.6 ± 31.3 175.7 ± 29.1 177.6 ± 27.1 182.7 ± 30.0 186.5 ± 29.6
LDL-C (mg/dL) 95.1 ± 23.3 92.6 ± 22.6 90.6 ± 21.8 92.5 ± 21.4 95.7 ± 22.2 97.7 ± 22.1
HDL-C (mg/dL) 75.3 ± 12.0 73.2 ± 10.9 71.3 ± 10.3 72.8 ± 10.4 75.4 ± 11.6 77.0 ± 11.6
Sd-LDL-C (mg/dL) 20.3 ± 13.6 16.5 ± 4.9 15.3 ± 5.3 16.1 ± 4.6 16.8 ± 5.5 16.7 ± 5.2
OxLDL (U/mL) 6.55 ± 4.15 5.86 ± 3.91 6.06 ± 4.99 6.17 ± 4.48 6.37 ± 3.83 6.92 ± 4.10
TG (mg/dL) 57.3 ± 16.8 72.7 ± 24.6 82.6 ± 28.3‖ 63.7 ± 17.0 52.8 ± 12.4 45.2 ± 10.3
Non-HDL-C (mg/dL) 106.1 ± 25.9 105.4 ± 25.8 104.4 ± 24.2 104.8 ± 23.2 107.3 ± 24.3 109.5 ± 23.9
RemL-C (mg/dL) 2.73 ± 0.95 3.47 ± 1.16 3.11 ± 1.13 2.83 ± 0.95 2.60 ± 0.77 2.45 ± 0.69
RLP-C (mg/dL) 2.62 ± 0.60 3.16 ± 1.06 3.90 ± 1.22‡ 2.98 ± 0.88 2.66 ± 0.72 2.52 ± 0.54
RLP-TG (mg/dL) 15 19.4 ± 7.0 25.5 ± 11.0‡ 16.2 ± 2.1 15.0 ± 0.2 15
ApoA-I (mg/dL) 168.7 ± 21.0 167.3 ± 21.8 164.8 ± 18.5 167.3 ± 17.3 170.7 ± 20.1 172.7 ± 20.3
ApoA-II (mg/dL) 36.0 ± 4.6 35.4 ± 4.7 34.6 ± 4.4 35.3 ± 4.3 35.8 ± 4.1 36.5 ± 4.5
ApoB (mg/dL) 63.7 ± 13.6 62.2 ± 12.9 61.5 ± 12.5 62.6 ± 12.2 64.4 ± 12.6 65.8 ± 12.4
ApoC-II (mg/dL) 2.8 ± 1.1 2.9 ± 1.1 2.9 ± 1.1 2.9 ± 1.0 2.9 ± 1.0 2.9 ± 1.1
ApoC-III (mg/dL) 9.1 ± 2.0 9.3 ± 2.0 8.9 ± 1.7 8.8 ± 1.6 8.6 ± 1.8 8.7 ± 1.8
ApoE (mg/dL) 4.7 ± 1.0 4.6 ± 1.1 4.5 ± 1.1 4.5 ± 1.1 4.5 ± 1.1 4.6 ± 1.1
Non-HDL-C/HDL-C 1.43 ± 0.38 1.46 ± 0.40 1.48 ± 0.39 1.47 ± 0.40 1.45 ± 0.39 1.45 ± 0.37
LDL-C/HDL-C 1.28 ± 0.33 1.28 ± 0.33 1.29 ± 0.33 1.29 ± 0.34 1.29 ± 0.33 1.29 ± 0.32
ApoB/apoA-I 0.38 ± 0.08 0.37 ± 0.08 0.38 ± 0.08 0.38 ± 0.08 0.38 ± 0.08 0.38 ± 0.08
Non-HDL-C/apo B 1.66 ± 0.11 1.68 ± 0.09 1.69 ± 0.11 1.67 ± 0.08 1.66 ± 0.10 1.66 ± 0.10
TG/apoB 0.92 ± 0.26 1.17 ± 0.32‡ 1.36 ± 0.40† 1.04 ± 0.29 0.84 ± 0.22 0.70 ± 0.17
Plasma glucose (mg/dL) 88.3 ± 5.2 95.8 ± 20.6 89.9 ± 12.1 85.5 ± 5.0 87.1 ± 5.1 86.5 ± 5.7
Insulin (μU/mL) 6.5 ± 2.6 54.1 ± 31.1‡ 27.9 ± 15.7‡ 5.6 ± 2.4 4.8 ± 1.8 3.9 ± 1.5
Apo, apolipoprotein; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; OxLDL, oxidized LDL; RemL-C, remnant lipoprotein
cholesterol measured using “MetaboLead RemL-C”; RLP-C, remnant-like particle-cholesterol measured with “JIMRO II”; RLP-TG, remnant-like particle-triglycerides;
Sd-LDL-C, small, dense-LDL cholesterol; TC, total cholesterol; TG, triglycerides. TG, RemL-C, RLP-C, RLP-TG, and TG/apoB were transformed into logarithmic values.
Values are expressed as means ± SD. *p < 0.05, †p < 0.005, ‡p < 0.0001, §p < 0.01, ‖p < 0.001, vs. time 0 (repeated ANOVA with Dunnett’s test).
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women.
Correlation between fasting adiponectin concentration
and fasting lipids and their parameters
There was no significant correlation between adiponec-
tin and several factors (Table 3). As for LPL mass, al-
though we had data from only 21 subjects (men 15,
women 6) in the fasting period, a significant correlation
with adiponectin was observed in all subjects.
We examined the correlation between fasting adiponec-
tin concentration and fasting lipids and their parameters
(Table 4). Fasting adiponectin concentration positively
correlated with HDL-C and apoA-I concentrations, and
negatively correlated with values of TG, RemL-C, RLP-C,
RLP-TG, non-HDL-C/HDL-C, LDL-C/HDL-C, and TG/apoB. After test meal loading, fasting adiponectin concen-
tration positively correlated with HDL-C and apoA-I con-
centrations, and negatively correlated with the values of
TG, RemL-C, RLP-C, RLP-TG, non-HDL-C/HDL-C,
LDL-C/HDL-C, apoB/apoA-I, and TG/apoB from 1 h to
8 h, fully or partially. Thus, fasting adiponectin concentra-
tion negatively correlated with postprandial elevation of
lipids and their parameters.
When we examined the relationship between fasting
LPL mass and lipids and their parameters before and
after test meal loading, there was no significant correl-
ation except some cases of apoC-II at 0, 1, 4, 6, and 8 h
and insulin at 6 h (r=−0.44, r=−0.44, r=−0.48, r=−0.47
r=−0.50, r=−0.50, respectively, all p<0.05).
We also examined the relationship between adiponec-
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Figure 1 Correlation between fasting values and the iAUC of TG, RemL-C, RLP-C, RLP-TG, and TG/apoB. TG, RemL-C, RLP-C, RLP-TG, and
TG/apoB were transformed into logarithmic values. Correlations were calculated using the formula for Pearson’s correlation coefficient. Apo,
apolipoprotein; RemL-C, remnant lipoprotein cholesterol assayed using “MetaboLead RemL-C”; RLP-C, remnant-like particle-cholesterol assayed
using “JIMRO II”; RLP-TG, remnant-like particle-triglyceride; TG, triglycerides.
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http://www.lipidworld.com/content/11/1/146adiponectin concentration significantly and negatively
correlated with the values of TG, RemL-C, RLP-C, RLP-
TG, and TG/apoB, but not with other factors (Fig. 2).
When we examined the relationship between LPL and
iAUC of them, there was no significant correlation
(r=−0.02, p=0.94; r=−0.11, p=0.64; r=−0.24, p=0.30;
r=−0.14, p=0.56; r=0.04, p=0.87, respectively).
Multivariable linear regression analysis for postprandial
TG elevation
Because TG strongly correlated with TRL-related values
such as RemL-C, RLP-C, RLP-TG, and TG/apoB
(r=0.90, r=0.80, r=0.80, r=0.83, p<0.0001, respectively),
we constructed the model of multivariable linearTable 3 Correlation between adiponectin and other
characteristics
Total Men Women
r p r p r p
Height (m) -0.16 0.31 0.05 0.83 0.24 0.33
Body weight (kg) -0.19 0.20 0.01 0.96 -0.01 0.97
Waist circumference (cm) -0.26 0.09 -0.08 0.70 -0.21 0.39
BMI (kg/m2) -0.15 0.33 -0.01 0.95 -0.33 0.17
HbA1c (%) -0.04 0.77 0.02 0.94 -0.14 0.58
Hs-CRP (mg/dL) -0.21 0.17 -0.07 0.75 -0.15 0.53
LPL mass (ng/mL) 0.54 0.01 0.34 0.21 0.81 0.05
BMI; body mass index, HbA1c; glycated hemoglobin A1c, Hs-CRP; high-
sensitivity C-reactive protein, LPL; lipoprotein lipase. Adiponectin was
transformed into logarithmic value. Correlation of adiponectin with other
markers was analyzed by Pearson’s correlation coefficient. All factors were
derived from 45 subjects (men 26, women 19) except LPL mass (total 21, men
15, women 6).regression analysis without fasting TG and adjusted by
sex, BMI, age, and waist circumference as we described
in Methods. RemL-C, RLP-C, RLP-TG, and TG/apoB
were significant factors, but adiponectin was not
(Table 5). Especially, adjusted R-squared of RemL-C and
TG/apoB were 0.63 and 0.55, respectively. Considering
the correlation between fasting adiponectin and fasting
lipids, we performed multivariable linear regression ana-
lysis without lipids and their parameters. However, we
could not uncover a significant relationship between
fasting adiponectin concentrations and postprandial TG
elevation (p = 0.09).
Discussion
The present study demonstrated that fasting TRL-
related values of TG, RemL-C, RLP-C, RLP-TG, and
TG/apoB were useful tools for predicting postprandial
hyperlipidemia and that fasting adiponectin concentra-
tions correlated with the fasting values of these lipids
and parameters in young healthy individuals, although
adiponectin was not a significant predictor in multivari-
able linear regression analysis.
Many studies have examined the relationship be-
tween adiponectin and dyslipidemia. Baratta et al.
reported that the relationship between adiponectin and
fasting lipid values is independent of body fat mass
[21]. Kazumi et al. and Heliövaara et al. demonstrated
that hypoadiponectinemia is more closely related to
adiposity and fasting dyslipidemia than insulin resist-
ance in young healthy men [22,23]. Interestingly,
Yoshida et al. demonstrated the lower adiponectin
concentrations in type IIb hyperlipidemia compared to
Table 4 Correlation between adiponectin and parameters concerning lipid and glucose metabolism before and after
loading the test meal
0 1 h 2 h 4 h 6 h 8 h
r r r r r r
TC (mg/dL) 0.09 0.08 0.06 0.05 0.08 0.06
LDL-C (mg/dL) -0.06 -0.06 -0.07 -0.09 -0.08 -0.09
HDL-C (mg/dL) 0.43* 0.43* 0.45* 0.42* 0.41* 0.41***
Sd-LDL-C (mg/dL) -0.11 -0.24 -0.26 -0.26 -0.18 -0.16
OxLDL (U/mL) 0.03 0.06 0.05 0.08 0.02 0.03
TG (mg/dL) -0.42*** -0.39*** -0.40*** -0.48* -0.40*** -0.42*
Non-HDL-C (mg/dL) -0.12 -0.13 -0.15 -0.17 -0.13 -0.15
RemL-C (mg/dL) -0.35**** -0.30**** -0.37**** -0.44*** -0.33**** -0.34****
RLP-C (mg/dL) -0.38**** -0.36**** -0.39*** -0.45*** -0.28 -0.35****
RLP-TG (mg/dL) -0.35** -0.30**** -0.36**** -0.42* -0.38**** -0.34****
ApoA-I (mg/dL) 0.34**** 0.37**** 0.35**** 0.33**** 0.34**** 0.35****
ApoA-II (mg/dL) -0.06 -0.07 -0.11 -0.11 -0.07 -0.07
ApoB (mg/dL) -0.09 -0.10 -0.13 -0.13 -0.12 -0.13
ApoC-II (mg/dL) -0.29 -0.27 -0.27 -0.32**** -0.27 -0.24
ApoC-III (mg/dL) -0.21 -0.18 -0.21 -0.27 -0.20 -0.13
ApoE (mg/dL) 0.06 0.06 0.03 0.02 0.08 0.10
Non-HDL-C/HDL-C -0.37**** -0.38*** -0.38*** -0.38*** -0.37**** -0.38***
LDL-C/HDL-C -0.34**** -0.35**** -0.35**** -0.35**** -0.35**** -0.36****
ApoB/ApoA-I -0.29 -0.31**** -0.31**** -0.30 -0.31**** -0.32****
Non-HDL-C/ApoB -0.21 -0.21 -0.14 -0.26 -0.11 -0.14
TG/apoB -0.40*** -0.39*** -0.37**** -0.43*** -0.33**** -0.35****
Plasma glucose x(mg/dL) -0.12 -0.06 -0.04 -0.13 -0.12 -0.11
Insulin (μU/mL) -0.17 -0.02 -0.07 -0.22 -0.33**** -0.22
TC; total cholesterol, LDL-C; low-density lipoprotein-cholestrol, HDL-C; high-density lipoprotein-cholesterol, Sd-LDL; small, dense-LDL, OxLDL; oxidized LDL, TG;
triglycerides, RemL-C; remnant lipoprotein cholesterol measured with “MetaboLead RemL-C”, RLP-C; remnant-like particle-cholesterol measured with “JIMRO II”,
RLP-TG; remnant-like particle-triglycerides, Apo; apolipoprotein. TG, RemL-C, RLP-C, RLP-TG, TG/apoB and adiponectin were transformed into logarithmic values.
Correlation of adiponectin with other markers was analyzed by Pearson’s correlation coefficient. *p<0.005, **p<0.001, ***p<0.01, ****p<0.05.
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in type II diabetes patients [24]. On the other hand,
the relationship between adiponectin and postprandial
hyperlipidemia has not been investigated in detail.
Rubin et al. demonstrated that postprandial plasma
adiponectin values decreased after oral loading with
75 g of glucose or with a high-fat meal (58 g of fat)
and that postprandial TG concentrations correlated
with fasting adiponectin concentration in a 45- to 65-
year-old population including those with metabolic
syndrome [16]. Moreover, Maruyama et al. found lower
TG and RLP-TG concentrations among individuals
with type 1 diabetes and a high, rather than a low
baseline HMW adiponectin concentration at baseline
and at 3 h after test meal loading [17]. The present
study demonstrated that fasting adiponectin concentra-
tion positively correlated with fasting HDL-C and
apoA-I concentrations, and negatively correlated withfasting and postprandial values of TG, RemL-C, RLP-
C, RLP-TG, non-HDL-C/HDL-C, LDL-C/HDL-C and
TG/apoB. These are new findings compared with our
previous study [11]. However, multivariable linear re-
gression analysis showed that adiponectin was not sig-
nificant for predicting postprandial hyperlipidemia,
which is difficult to explain. Adiponectin participates
in the metabolism of the visceral fat mass, glucose and
lipids, but it might not reflect dynamic changes such
as lipid concentrations that elevate after test meal
loading. In addition, the small number of samples
derived from only healthy subjects might have affected
this finding. Patients with hyperlipidemia, diabetes or
metabolic syndrome often have delayed TRL clearance
[10]. Although we may find other results if we include
older subjects or these patients, it is also necessary to
elucidate the significant predictive factors in young
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Figure 2 Correlation between fasting adiponectin concentration and the iAUC of TG, RemL-C, RLP-C, RLP-TG, and TG/apoB. TG, RemL-C,
RLP-C, RLP-TG, TG/apoB, and adiponectin were transformed into logarithmic values. Correlations were calculated using the formula for Pearson’s
correlation coefficient. Apo, apolipoprotein; RemL-C, remnant lipoprotein cholesterol assayed using “MetaboLead RemL-C”; RLP-C, remnant-like
particle-cholesterol assayed using “JIMRO II”; RLP-TG, remnant-like particle-triglyceride; TG, triglycerides.
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http://www.lipidworld.com/content/11/1/146study is to elucidate the significant predictors of post-
prandial TG elevation. On the other hand, since adipo-
nectin concentrations are considerably higher in
women than in men, the significance of adiponectin
needs to be separately analyzed in men and women.
A definition or standard method other than TG eleva-
tion has not been established for predicting postprandial
hyperlipidemia. This complicates resolving which factor
among those associated with postprandial hyperlipidemia
is the most useful for predicting CVD. Some studies have
demonstrated the superiority of non-fasting, over fasting
TG concentrations for predicting CVD [6,7]. Oka et al.
notably demonstrated that waist circumference is more
closely related to postprandial, than to fasting TG [25].
Moreover, the lipid profile in metabolic syndrome
includes elevated TG and remnant lipoproteins, deTable 5 Multivariable linear regression analysis for postprand
circumference)
β Coefficient SE 95 % CI
RemL-C 0.67 0.09 0.48 to 0.86
RLP-C 0.71 0.17 0.37 to 1.06
RLP-TG 1.21 0.36 0.48 to 1.93
TG/apoB 0.81 0.13 0.54 to 1.08
Adiponectin -0.21 0.12 -0.45 to 0.03
SE; standard error, CI; confidence interval, BMI; body mass index, TG; triglyceride, Re
RLP-C; remnant-like particle-cholesterol measured with “JIMRO II”, RLP-TG; remnant-
and adiponectin were transformed into logarithmic values.creased LDL particle size and low HDL-C concentrations
[10]. Thus, not only fasting TG values, but also other
parameters might be required to assess CVD risk.
Remnant lipoproteins play an important role in athero-
genesis and their concentrations are useful to understand
metabolic disorders and to predict CVD [10,26,27]. Ai
et al. reported that RLP-C and RLP-TG, but not the TG
response to an oral fat load are significantly increased in
hyperinsulinemic patients with type 2 diabetes [28]. We
also found that fasting serum concentrations of remnant
lipoproteins might be useful to detect postprandial hyper-
lipidemia even in normolipidemic individuals [11]. Here,
we confirmed that remnant lipoproteins during the fast-
ing period can predict postprandial hyperlipidemia. The
purpose of our study was to elucidate the factors that
predict postprandial hyperlipidemia besides TG, becauseial TG elevation (adjusted by sex, BMI, age, and waist







mL-C; remnant lipoprotein cholesterol measured with “MetaboLead RemL-C”,
like particle-triglycerides, Apo; apolipoprotein. RemL-C, RLP-C, RLP-TG, TG/apoB
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http://www.lipidworld.com/content/11/1/146it is difficult to select high-risk patients with TG alone.
However, TG strongly correlated with TRL-related values
including RemL-C, RLP-C, RLP-TG, and TG/apoB, so we
constructed the regression model without fasting TG.
Multivariable linear regression analysis identified RemL-
C, RLP-C, RLP-TG, and TG/apoB as significant predic-
tors of postprandial TG elevation. Taking these findings
together, these TRL-related values might be clinically use-
ful for predicting postprandial hyperlipidemia.
Another novel outcome of the present study is that the
amount of postprandial lipid elevation differs between
men and women. Fasting values of TG, RemL-C, RLP-C,
RLP-TG, non-HDL-C/HDL-C, LDL-C/HDL-C, and
apoB/apoA-I were significantly greater in men than in
women (Table 2B and C). Furthermore, the iAUCs of
TG, RemL-C, RLP-C, RLP-TG, and TG/apoB were also
significantly greater in men than in women. These results
suggest that men are more susceptible to postprandial
hyperlipidemia. The difference in lipoprotein metabolism
between men and women may be caused by several
mechanisms including lipoprotein lipase and lecithin-
cholesterol acyltransferase activities (LCAT) activities,
and gender specific hormonal effects [8-10,29]. Higher
adiponectin concentrations in women may also influence
TRL metabolism (Table 1) [14,15,21-24]. Although we
did not check the activities of enzymes and menstrual
cycle of each woman in the present study, these differ-
ences in fasting and postprandial TRL-related lipid con-
centrations between men and women should be
considered when distinguishing and predicting indivi-
duals at high-risk for postprandial hyperlipidemia.
We measured the serum concentrations of several lipid
markers. Postprandial accumulation of TRL was strongly
associated with the increased prevalence of sd-LDL in
patients with myocardial infarction [30]. However, sd-LDL
concentrations were decreased in the present study of
young healthy individuals. Ogita et al. demonstrated that
serum sd-LDL concentrations decrease after meals, in-
crease during the night and peak just before breakfast
[31]. Hirayama et al. also demonstrated a similar decrease
in the sd-LDL concentrations after breakfast; they specu-
lated that sd-LDL permeates the vascular walls more eas-
ily, and might be more susceptible than buoyant LDL to
entrapment in vascular subendothelial spaces [32]. The
precise mechanism should be addressed in future studies.
Regardless, postprandial changes in sd-LDL might differ
between healthy individuals and patients with CVD.
We also found that the oxidized LDL concentration did
not significantly change. Although oxidized LDL in
patients with CAD is postprandially elevated [33], concen-
trations in healthy individuals have not been investigated
in detail. One study has found that oxidized LDL concen-
trations are not elevated in individuals with normal glu-
cose tolerance during oral glucose tolerance test [34].Postprandial changes in oxidized LDL concentrations
should be examined and compared with those of patients
with CAD.
Non HDL-C is an excellent predictor of atheroscler-
otic risk [35,36] and it is free of dietary variations
[36,37]. Ogita et al. also demonstrated that serum con-
centrations of TC, HDL-C, and LDL-C do not change
remarkably in healthy individuals [31]. The present study
also did not identify significant changes in TC, HDL-C,
LDL-C and non HDL-C concentrations among young
healthy individuals. Some studies have demonstrated
that LDL-C and HDL-C concentrations decrease during
the day in a rhythmic circadian manner [38,39]. We also
found decreased LDL-C and HDL-C concentrations, but
the changes were not statistically significant. Thus, TC
and non HDL-C concentrations were not significantly
altered, although the postprandial value of remnant
cholesterol was increased.
This study has some limitations. Although others have
associated adiponectin concentrations with body weight,
waist circumference, BMI, HbA1c and hs-CRP [40,41],
we found no significant correlations because we mea-
sured these values in young individuals without meta-
bolic syndrome or diabetes.
The RemL-C concentrations increased after test meal
loading, albeit without significance, which is consistent
with previous findings [11]. Lipoproteins targeted by
both RLP-C and RemL-C include remnants of both chy-
lomicrons and VLDL [10]. Concentrations of RemL-C
and RLP-C closely correlate in patients with coronary ar-
tery disease, but the sensitivity of detecting chylomicron
remnant (exogenous) and VLDL remnant (endogenous)
lipoproteins might differ between analytical methods
[10]. By detailed analysis with the high performance liquid
chromatography method, Yoshida et al. demonstrated that
they found higher concentrations of chylomicron choles-
terol in serum samples with RemL-C < RLP-C, but high
concentrations of intermediate-density lipoprotein (IDL)-
cholesterol (VLDL remnant cholesterol) in samples with
RemL-C > RLP-C [42]. Similarly, we and others also
reported that methods for measuring RLP-C and RLP-TG
might be more sensitive to chylomicron remnant-
cholesterol and -triglycerides, whereas those for RemL-C
might be more suitable for IDL-cholesterol [11,20,43].
This may cause a difference in elevation after test meal
loading and in multivariable linear regression analysis be-
tween RemL-C and RLP-C in the present study.
We did not evaluate the effect of activities such as
aerobic exercise that can decrease TG and remnant
concentrations and increase adiponectin concentrations
[44]. Factors that can predict postprandial hyperlipid-
emia should be investigated in larger populations in-
cluding individuals with metabolic syndrome, diabetes
and CVD.
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Fasting TRL-related values, especially RemL-C, RLP-C,
RLP-TG, and TG/apoB are useful predictors of post
prandial hyperlipidemia in young healthy individuals. Al-
though the fasting adiponectin concentration correlates
with the fasting values of TG, RemL-C, RLP-C, RLP-TG
and TG/apoB, it is not a significant predictor of postpran-
dial hyperlipidemia in multivariable linear regression
analysis.
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